VACCINE AVAILABILITY

While the delivery of limited amounts of vaccines has begun throughout the State, the latest guidance from the State on vaccine availability and priority populations is available online through the State of Connecticut COVID 19 portal.

VACCINE INFORMATION - DARIEN

The Town of Darien has formed a Vaccine Distribution Committee consisting of Public Health professionals, medical professionals, emergency response planners and logistics experts. The Committee has developed a mass vaccination plan for the rapid and orderly distribution of the vaccine as it becomes available to the Town, based on state and federal distribution guidelines. Darien is in the process of placing orders this week to vaccinate phase 1a populations through the statewide ordering system and hope to be able to provide vaccines to those groups during the first week of January.

There is currently no definitive direction from the State of Connecticut as to when vaccine distribution will commence for phase 1b, however the general guidance is that the State will "expect Phase 1b to begin in the first quarter of 2021." The Town of Darien will be prepared to quickly commence delivering vaccine to 1b populations once given direction from the State of Connecticut.

For phase 1a, the vaccine the Town of Darien will be receiving is produced by Moderna. For information on the Moderna vaccine, including any side effects, efficacy, safety and contraindication information, please refer to the following information:

Moderna COVID-19 Vaccine website	Telephone number
www.modernatx.com/covid19vaccine-eua	1-866-MODERNA (1-866-663-3762)

*The **most common solicited adverse reactions associated with mRNA-1273** were **injection site pain (91.6%), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint pain (44.8%),** and 6 Moderna COVID-19 Vaccine VRBPAC Briefing Document chills (43.4%); **severe adverse reactions occurred in 0.2% to 9.7% of participants, were more frequent after dose 2 than after dose 1, and were generally less frequent in participants ≥65 years of age as compared to younger participants.** Among unsolicited adverse events of clinical interest, which could be possibly related to vaccine, using the November 25, 2020 data cutoff, lymphadenopathy was reported as an unsolicited event in 173 participants (1.1%) in the vaccine group and 95 participants (0.63%) in the placebo group. Lymphadenopathy (axillary swelling and tenderness of the vaccination arm) was a solicited adverse reaction observed after any dose in 21.4% of vaccine recipients.*